Specifically, regarding immunohistochemistry, inclusion criteria were HER2-negative and CLDN18.2-positive tumors, where the threshold for considering a case as positive for CLDN18.2 was set at 75% of tumor cells demonstrating moderate to high membranous staining [18, 20]. Here, CLDN18 is linked to neoplasm.